StageZero Life Sciences Ltd (TSE:SZLS) has released an update.
StageZero Life Sciences, a healthcare company specializing in multi-cancer diagnostics, has reported improved financial performance in Q2 2024, following operational changes and the resumption of its Aristotle test. The company is focusing on strategic partnerships to expand the test’s uptake and anticipates revenue growth, with Q3 already showing an increase compared to the first half of the year.
For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.